文献速递血管炎

皮肤型结节性多动脉炎的治疗选择:一项系统综述

Therapeutic options for cutaneous polyarteritis nodosa: a systematic review.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

全身糖皮质激素广泛用于诱导治疗,免疫抑制剂及多种其他药物也被使用;部分研究中溃疡与复发风险增加相关。关于CPAN治疗的证据非常有限,需进一步研究评估治疗对缓解、复发和死亡率的影响。

要点

  • 全身糖皮质激素广泛用作CPAN诱导治疗。
  • 免疫抑制剂常与糖皮质激素联用,包括AZA、HCQ、SSZ等。
  • 部分研究中溃疡与复发风险增加相关。

核心结论

  • 关于CPAN患者管理的现有证据非常有限,需进一步研究评估治疗对疾病缓解、复发和死亡率的影响。

研究设计与样本

  • 纳入7项评估成人CPAN管理的病例系列,共325例独特患者,无研究包含对照人群。

主要发现

  • 全身糖皮质激素广泛用作诱导治疗。
  • 与糖皮质激素联用的免疫抑制剂包括AZA、羟氯喹、柳氮磺吡啶、柳氮磺吡啶类似物、CYC、MTX、吗替麦考酚酯、他克莫司、利妥昔单抗和沙利度胺。
  • 其他使用的药物包括氨苯砜、秋水仙碱、非甾体抗炎药、水杨酸盐、华法林和氯吡格雷。
  • 部分研究中溃疡的存在与复发风险增加相关。

临床怎么用

  • CPAN治疗可考虑全身糖皮质激素作为诱导治疗,免疫抑制剂常与糖皮质激素联用。
  • 对伴溃疡的CPAN患者需关注复发风险增加的可能性。

局限性

  • 纳入研究均为病例系列,无对照人群,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cutaneous polyarteritis nodosa (CPAN) is a necrotizing vasculitis of the middle-size vessels, confined to the skin. We conducted a systematic review in order to identify studies evaluating the different treatment modalities used in CPAN. METHODS: This systematic review was conducted according to PRISMA guidelines, registered in PROSPERO: CRD42020222195. PubMed/Medline databases were searched from inception to December of 2020 using the terms: (Polyarteritis nodosa[Title/Abstract]) AND ((therapy[Title/Abstract]) OR (management[Title/Abstract]) OR (treatment[Title/Abstract]))' and 'Cutaneous arteritis [Title/Abstract]'. Articles evaluating pertaining to the management of CPAN in adults were eligible for inclusion. RESULTS: A total of seven eligible case series with 325 unique patients were included. No study included a control population. In general, systemic corticosteroids were widely used as induction treatment. Immunosuppressive agents combined with corticosteroids were AZA, hydroxychloroquine, sulfasalazine, sulphapyridine, CYC, MTX, mycophenolate, tacrolimus, rituxima and thalidomide. Other agents utilized in the studies were dapsone, colchicine, non-steroid anti-inflammatory drugs, salicylates, warfarin and clopidogrel. In some studies, the presence of ulcerations was associated with an increased risk of relapse. CONCLUSION: The evidence available regarding the management of patients with CPAN is limited at best. Further studies are needed in order to evaluate the effect of treatment on disease remission, relapses and mortality.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Papachristodoulou E, Kakoullis L, Tiniakou E, et al. Therapeutic options for cutaneous polyarteritis nodosa: a systematic review. Rheumatology (Oxford). 2021. PMID: 33944902. doi:10.1093/rheumatology/keab402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。